SAB Biotherapeutics (SABS) Expected to Announce Quarterly Earnings on Wednesday

SAB Biotherapeutics (NASDAQ:SABS) is anticipated to issue its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.59) per share for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 7:00 AM ET.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.27). On average, analysts expect SAB Biotherapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

SAB Biotherapeutics Price Performance

NASDAQ SABS opened at $3.02 on Wednesday. SAB Biotherapeutics has a twelve month low of $1.00 and a twelve month high of $6.60. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.87 and a current ratio of 0.87. The stock has a market capitalization of $31.44 million, a PE ratio of -0.76 and a beta of 0.54. The stock has a 50-day simple moving average of $2.32 and a 200 day simple moving average of $2.08.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Wall Street Zen raised SAB Biotherapeutics to a “sell” rating in a research report on Saturday, September 20th. Leerink Partnrs raised SAB Biotherapeutics to a “strong-buy” rating in a research report on Wednesday, September 17th. Leerink Partners assumed coverage on SAB Biotherapeutics in a research report on Wednesday, September 17th. They set an “outperform” rating and a $7.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of SAB Biotherapeutics in a research report on Tuesday, October 14th. Finally, Chardan Capital reissued a “buy” rating and set a $12.00 target price on shares of SAB Biotherapeutics in a research report on Friday, September 19th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, SAB Biotherapeutics presently has an average rating of “Moderate Buy” and an average price target of $9.33.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.